Albania vs Low & middle income: Immunization, Hib3
Albania
97.0%
in 2024
Low & middle income
75.7%
in 2024
Albania rank
29th
Low & middle income rank
29th
Immunization, Hib3 over time
- Albania
- Low & middle income
How they compare
Albania currently reports 97.0% against 75.7% in Low & middle income, a difference of 21.3%.
That makes Albania's figure about 1.3 times Low & middle income's.
Across all 16 years both countries report, Albania has been ahead every year.
Albania ranks 29th and Low & middle income ranks 29th of 191 countries.
Albania has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Albania | Low & middle income | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 98.0% | 34.2% | 63.8% | Albania |
| 2010s | 99.0% | 55.3% | 43.7% | Albania |
| 2020s | 97.4% | 72.8% | 24.6% | Albania |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher immunization, hib3, Albania or Low & middle income?
- Albania, at 97.0% against 75.7% in Low & middle income as of 2024.
- What is the difference in immunization, hib3 between Albania and Low & middle income?
- 21.3%, with Albania ahead.
- How many years of comparable data are there for Albania and Low & middle income?
- 16 years are reported by both, from 2009 to 2024.
- How do Albania and Low & middle income rank globally for immunization, hib3?
- Albania ranks 29th and Low & middle income ranks 29th of 191 countries.
- Where does this data come from?
- WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as Immunization, Hib3 (% of children ages 12-23 months). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.